levcromakalim

Small moleculeexperimental

Cromakalim (INN) is a potassium channel-opening vasodilator. The active isomer is levcromakalim. It acts on ATP-sensitive potassium channels and so causes membrane hyperpolarization. It can be used to treat hypertension as it will relax vascular smooth muscle to lower blood pressure. Hyperpolarisation of smooth muscle cell membranes pulls their membrane potential away from the threshold, so making it more difficult to excite them and thereby cause relaxation. — Wikipedia

Clinical trial activity

11 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started May 24, 2017 (NCT03228355)

Timeline

No events for the selected filters.

Chemistry & pharmacology

Loading structure…

SMILES

CC1(C)Oc2ccc(C#N)cc2[C@@H](N2CCCC2=O)[C@@H]1O
Mol. weight
286.33 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05889442N/AMar 9, 2023Novartis, University of Copenhagen
NCT05565001N/ASep 1, 2022University of Copenhagen
NCT05243953N/AMar 21, 2022University of Copenhagen
NCT05211050N/AFeb 15, 2022University of Copenhagen
NCT04905654N/ASep 29, 2021University of Copenhagen
NCT05093582N/AJun 4, 2021University of Copenhagen
NCT04012047N/AJul 10, 2019University of Copenhagen
NCT03886922N/AApr 1, 2019University of Copenhagen
NCT03726242N/ANov 1, 2018University of Copenhagen
NCT03609008N/AJun 26, 2018University of Copenhagen
NCT03228355N/AMay 24, 2017University of Copenhagen
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of CopenhagenAcademic/Hospital111112017
NovartisFor profit1012023
2 organizations
Page 1 / 1